Curated News
By: NewsRamp Editorial Staff
August 10, 2026
Tonix Pharmaceuticals Reports Strong Q2 2026 Results Driven by TONMYA
TLDR
- Tonix Pharmaceuticals reports 575% revenue growth, driven by TONMYA, with 136 million lives covered and potential expansion to 145 million by 2027.
- Tonix's Q2 2026 revenue surge to $13.5M from $2M is fueled by TONMYA sales, with prescriptions up 100% sequentially, and pipeline advances in depression and Lyme.
- Tonix's TONMYA, first new fibromyalgia treatment in 15 years, expands access to 136 million patients, improving quality of life for chronic pain sufferers.
- TONMYA prescriptions soared 207% for refills, and a new Phase 2 study for major depressive disorder could broaden its use beyond fibromyalgia.
Impact - Why it Matters
This news matters because it signals a significant commercial milestone for Tonix Pharmaceuticals, demonstrating the market acceptance of TONMYA as a new treatment for fibromyalgia, a condition that has had limited therapeutic options for over 15 years. The substantial revenue growth and expanding patient access indicate potential long-term viability and profitability for the company, which could positively affect investors. Moreover, the progress in the clinical pipeline, including potential treatments for major depressive disorder and Lyme disease, highlights the company's commitment to addressing high unmet medical needs. For patients, this could mean new, more effective therapies on the horizon. For the biotech sector, it underscores the importance of innovation and the potential for successful commercialization of CNS and immunology drugs.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) has reported a strong second-quarter 2026 performance, with net product revenue reaching approximately $13.5 million, a significant jump from $2 million in the same period last year. This growth was driven by TONMYA, its recently approved treatment for fibromyalgia, which generated about $11 million in net sales. The drug saw 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills soaring 207%. TONMYA's market access is expanding, currently covering around 136 million lives across commercial, managed Medicare, and Medicaid channels, and expected to reach 145 million lives when a managed Medicare agreement takes effect on January 1, 2027.
Beyond its commercial success, Tonix is advancing its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, and is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review. With approximately $176.2 million in cash and cash equivalents at the end of the quarter, plus third-quarter equity proceeds, Tonix expects to fund operations into early second-quarter 2027. The company is a fully-integrated, commercial-stage biotechnology firm focused on central nervous system and immunology treatments. In addition to TONMYA, its CNS portfolio includes acute migraine products Zembrace SymTouch and Tosymra, and it is exploring TONMYA's potential in other indications. Immunology programs include TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention.
For more details, visit the full press release at https://nnw.fm/6Yytj. The latest news on TNXP is available in the company's newsroom at https://nnw.fm/TNXP. This announcement was distributed by NetworkNewsWire, a communications platform that is part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Reports Strong Q2 2026 Results Driven by TONMYA
